anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To address the rising incidence of non-communicable diseases (NCDs) and promote healthier eating habits, Japan requires a culturally tailored Nutrient Profile Model. This study aimed to develop a Nutrient Profile Model for Dishes in Japan version 1.0 (NPM-DJ (1.0)) that corresponds to the nutritional issues and food culture in Japan. The aim of the NPM-DJ (1.0) was to promote the health of the general population, and to prevent the increase in NCDs in Japan. The NPM-DJ (1.0) categorizes dishes into staples, sides, mains, mixed dishes, and mixed dishes with staples. The model evaluates dishes based on energy, saturated fats, sugars, and sodium as restricted nutrients, while considering protein, dietary fiber, and the weight of certain food groups as recommended nutrients. The distribution of the overall score for each dish category was analyzed and a rating algorithm was created. The baseline, modification points, and final scores were significantly lower for side dishes than for staple dishes. In contrast, the baseline points and final scores were significantly higher for mixed dishes with staple. The model effectively differentiated nutritional profiles across five dishes categories, which may promote healthier dish reformulation by food businesses operators and encourage consumers to select healthier dishes.
PURPOSE:To obtain the subject agent capable of applying a nontacky film to dentures by directly adding polymer solid powder prepared by polymerizing tetrafluoroethylene according to a specific method without separating thereof from a dispersion and blending the resultant dispersion in a photo-setting resin, a photoinitiator and a solvent. CONSTITUTION:A coating agent containing a photo-setting resin, a photoinitiator, a solvent and dispersed fine powdery polytetrafluoroethylene is produced. Tetrafluoroethylene is polymerized in the presence of a radical polymerization initiator in a fluorine-based organic solvent to produce a fine powdery polymer dispersion. The resultant dispersion is added and blended in the photo-setting resin, photoinitiator and solvent without separating polymer solid powder. The aforementioned dispersion is more preferably added to a solution containing an organic solvent having a higher boiling point than that of the fluorine-based organic solvent, which is then substantially volatilized and removed. The obtained dispersion is subsequently blended with the aforementioned ingredients. Dentures coated with the above-mentioned coating agent are capable of preventing sticking to rice cakes, chewing gums, etc.
The invention disclosed a production technology of a turbot reddish body iridovirus inactivated vaccine which takes turbot fin cells as an amplification system of viruses. Iridovirus raw liquor is firstly prepared from viscera of a diseased fish being ill with viral reddish body syndrome, and turbot reddish body iridoviruses are inoculated on logarithmic phase turbot fin cells. The cells are added with MEM culture solutions ranging from 20 DEG C to 24 DEG C which contains 5-15 percent of calf serum after adsorbing viruses in the temperature ranging from 20 DEG C to 24 DEG C, and cultures are harvested. By freezing and thawing at 30 DEG C below zero for one to two times, amplification viruses in supernatant are collected in a centrifugal way to obtain sufficient virus liquor, inactivation treatment is carried out on the sufficient virus liquor for 36-60h in temperature ranging from 35 DEG C to 40 DEG C by using formalin solutions with terminal concentration of 0.1-0.5 percent, and inactivated virus vaccine raw liquor is obtained. When in use, the inactivated virus vaccine raw liquor is diluted by 10-20 times, and is added with aluminum hydroxide adjuvants with the terminal concentration of 3-5g/l to be manufactured into using liquor of the inactivated virus vaccine. The invention has the advantages of simple technology, favorable stability, and is suitable for scale production, can obtain large amount of inactivated virus vaccine and has favorable immunogenicity, as well as can be directly used for the preventive immunity of turbot, thereby the survival rate and the culture benefit of the turbot are improved.
The present invention relates to a glossy privet fruit and astragalus root freeze-dried powder injection preparation for injection and a making method thereof. The glossy privet fruit and astragalus root freeze-dried powder injection preparation comprises the ingredients of the following proportion by weight: 10 to 90% of glossy privet fruit and 90 to 10% of astragalus root. The preparation method is divided into the extraction process and the preparation process, wherein the extraction process comprises: extracting medicinal granules of the glossy privet fruit and the astragalus root with ionized water, combining extract liquor, filtering, concentrating the filter liquor into medicinal liquor, adding alcohol, settling and filtering to obtain precipitates and filter liquor to obtain the effective fraction of polysaccharide of the glossy privet fruit and the effective fraction of total saponins of astragalus root; the preparation process comprises: adding a right amount of water for injection to the effective fractions to dissolve the effective fractions, adding freeze-dried excipient vehicle and isoosmotic adjusting agents for injection, compounding into a solution with water for injection, adding active carbon for injection, boiling, filtering, regulating the pH value of the solution, filtering, packaging, freezing at low temperature and drying. The present invention has the advantages that the quality of samples is stable and meets the quality requirement of treatment. The route of administration is injection administration, and the present invention has the characteristics of outstanding curative effects and rapid effect taking. The medicine is in a solid state and has low water content, and thus, the medicine has strong stability and easy transportation and storage.
The immunopathogenesis of dengue severity remains an enigma. There is a growing body of evidence pointing towards a transient hyperinflammatory hypercytokinemic state responsible for the development of severe dengue including dengue hemorrhagic fever that coincides with the onset of thrombocytopenia, capillary leak, multiorgan dysfunction and hyperferritinemia. There are several reports of dengue associated hemophagocytic lymphohistiocytosis (HLH). However, the cytokine storm in dengue as well as in other infections may not conform to the classic HLH 2004 diagnostic criteria. Following the recent COVID-19 pandemic, there has been a paradigm shift in the understanding of infection-associated cytokine storms. There is a need to explore timely short-course immunotherapy for the management of selected patients with dengue spiraling into the critical phase.
Group (c) patients \[Those with M1 disease to receive biotherapy or chemotherapy\] will receive RGD-K5 scan prior to the beginning of the first line systemic therapy, two weeks after beginning of the first line systemic therapy, within two weeks of first response evaluation for the first line systemic therapy, and within two weeks after end of the first line systemic therapy; each RGD-K5 scan would be performed within two weeks of conventional image studies. The systemic therapy might be biotherapy or chemotherapy.
TRAIN-Vets is an 8-month intervention with aquatic-based exercise training and cognitive training combined with lifestyle coaching related to cognitive impairment risk factors. This intervention entails 6 months of thrice-weekly aquatic-based exercise training at Veterans Affairs Palo Alto Health Care System (VAPAHCS). After completion of the 6-months of exercise training, Veterans in this condition will participate in 2 months of weekly structured on-line cognitive training focused on improvement of executive function and attention based out of the San Francisco Veterans Affairs Health Care System (SFVAHCS). Concurrently, Veterans in TRAIN-Vets will also participate virtually in monthly lifestyle coaching based at SFVAHCS focused on other risk factors and symptoms.
The objective of this work was to evaluate the dynamics of anti-T. gondii antibodies and seroconversion in naturally infected goats from the last third of pregnancy to 100 days of lactation and relate it to hematological and dehydration parameters. Blood samples were obtained from 56 goats in the different physiological states (pregnancy, kidding and lactation) as in different years (2019, 2021 and 2022). A total of 266 serum samples were obtained and evaluated by indirect fluorescent antibody test (IFAT) to end titer. The overall T. gondii seropositivity was 80.4% (45/56), with titers ranging from 100 to 25.600. The goats older than 3 years (4967 ± 1329) had significantly higher IFAT titers than the younger goats (2705 ± 681). The highest rate of positive seroconversion 31.1% (14/45) was found between kidding and 70 days of lactation; and of negative seroconversion 28.9% (13/45) between late pregnancy and kidding. The highest proportion of slightly dehydrated animals was found in the last third of pregnancy (14/25) and kidding (9/28). The correlation between seroconversion and T. gondii antibody titers was negative to the established dehydration index. These data suggest that in all physiological states and at different ages of goats, there is seroconversion which is not related to hydration status. Pregnancy, kidding and peak of lactation are stressful physiological periods, facilitating the reactivation of chronic T. gondii infections which are expressed by higher antibodies titers.
About 25 subjects will be allocated to this group to receive semaglutide only, as one of the experimental groups. Semaglutide used in this trial is WEGOVY (semaglutide) injection produced by Novo Nordisk. Administer WEGOVY once weekly, on the same day each week, at any time of day, with or without meals. Inject subcutaneously in the abdomen, thigh or upper arm. Initiate at 0.25 mg once weekly for 4 weeks. In 4 week intervals, increase the dose until a dose of 1.0 mg is reached, and then maintained 1.0 mg until the end of treatment in total 12 weeks..
Polymeric nanoaggregate drug-delivery compositions including boron-containing copolymers are described. The drug-delivery compositions may further include a therapeutic agent comprising a nucleic acid, a polynucletide, a peptide, a polypeptide, a protein, a pharmaceutical or any combinations thereof. Methods for making the polymeric nanoaggregate compositions including at least one therapeutic agent (for example, insulin) as well as methods for administration of these compositions to mammals are also set forth. The disclosure also describes compositions and methods for controlled drug delivery. Further, polymeric nanoaggregate boron-containing compositions including insulin and methods for monitoring and regulating blood glucose levels of a mammal are also described. The disclosure also describes methods for treatment and/or control of diabetes mellitus by administering polymeric nanoaggregate boron-containing compositions including insulin to a mammal in need.
Solns. for parenteral administration contains a soluble salt of thioctic acid (I), in water at a concn. of 0.4-16 g/l.. USE/ADVANTAGE - (I) acts as a coenzyme in the oxidative decarboxylation of pyruvate and other alpha ketonic acids. It is used in the treatment of liver disorders, hepatic lesions, diabetic or alcoholic polyneuropathies, and metabolism disorders causing modification of peripheral nerves. Available ampoules of (I) currently available have a max. dosage of 250 mg. The usual dosage of 600 mg. therefore involves the use of several ampoules. The new solns. overcome this difficulty.
Clomiphene citrate (Clomid) is often used for assisted reproductive technologies and may be used to augment ovarian stimulation with exogenous gonadotropins by stimulating pituitary follicle-stimulating hormone (FSH) release in addition. The mechanism of action of Clomid is antagonism at the estrogen receptor, and this stimulates FSH release from the pituitary. The typical Clomid-based protocol has involved clomid only given for the first five days of stimulation to allow for endometrial development later in the cycle for a fresh embryo transfer following the oocyte retrieval. This protocol involves the addition of a GnRH antagonist medication later in the cycle to prevent premature ovulation. Recent national trends in IVF, however, have moved towards frozen embryo transfers and use of preimplantation genetic testing, which obviates any concerns regarding the endometrium. Recent experience in our clinic has suggested that Clomid may also prevent premature ovulation by antagonizing the positive feedback that is responsible for the luteinizing hormone (LH) surge and ovulation. Given in this manner, Clomid can be given throughout the duration of an ovarian stimulation cycle, achieve higher FSH levels and degree of ovarian stimulation in patients with diminished ovarian reserve, and obviate the need for GnRH antagonist medication (another expensive subcutaneous injection). The objective of this study is to compare a "long Clomid protocol" (i.e. using Clomid throughout the entire duration of the IVF cycle) as compared to the typical 5-day clomid protocol. The investigators hypothesize that the long Clomid protocol will be non-inferior to the typical five-day course and obviate the need for GnRH antagonist by preventing premature ovulation. Patients with diminished ovarian reserve and anticipated poor response to ovarian stimulation will be randomized to the long Clomid protocol vs. a 5-day Clomid with GnRH antagonist protocol. The primary outcome will be oocyte yield. Secondary outcome will be premature ovulation, embryo development, and pregnancy outcomes.
OBJECTIVE: Poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib and niraparib have shown promise in extending progression-free survival (PFS) in patients with platinum-sensitive recurrent (PSR) epithelial ovarian cancer. In this retrospective study, we aimed to present our own data on the effect of PARP inhibitors on PFS in recurrent epithelial ovarian cancer.
METHODS: 82 patients diagnosed with PSR epithelial ovarian, tubal, or primary peritoneal cancer between May 2017 and September 2023 were initially enrolled from our hospital. However, 16 patients had prior exposure to PARP inhibitors during primary treatment, and 11 were lost to follow-up. Consequently, the study focused on 55 eligible patients. PFS was compared between patients receiving PARP inhibitor maintenance therapy and those who did not.
RESULTS: Among the 55 patients with PSR epithelial ovarian cancer, 18 received olaparib as maintenance therapy, 19 received niraparib, and 18 opted for observation. PARP inhibitor therapy significantly extended PFS (mean 24.0 months) compared to observation (mean 9.0 months, p = 0.0005), regardless of BRCA mutation status (HR = 0.20, 95% CI: 0.08-0.50). Subgroup analysis showed no statistical difference between olaparib and niraparib. Additionally, there was no PFS difference based on BRCA mutation status within both PARP inhibitor groups.
CONCLUSION: Our retrospective study demonstrates that PARP inhibitor maintenance therapy, including olaparib and niraparib, significantly prolongs PFS in patients with PSR epithelial ovarian, tubal, or primary peritoneal cancer, These findings support the broad utilization of PARP inhibitors as a standard maintenance therapy for PSR epithelial ovarian cancer irrespective of BRCA mutation status.
Participants assigned to the experimental group will undergo HRV Biofeedback training using the Inner Balance Coherence Plus® software. This software incorporates a Bluetooth plethysmograph ear sensor, which will transmit cardiac pulse data to the Inner Balance Coherence Plus smartphone app, where the EmWave Pro® Plus software will extract HRV in real-time. This software will display the participant's HRV-BFB curve on their smartphone. The installation of the program and necessary instructions for its use will be provided at the first visit (V1). Fractional training sessions of 8 minutes will be recommended, twice daily for 30 days (during the period V1-V2 or the period V2-V3). Respiratory instructions will differ between the two interventions. During the HRV-BFB intervention, participants will be instructed to maximize their HRV.
FIELD: cosmetics, particularly, compositions for hair treatment. SUBSTANCE: composition contains at least one grafted silicon-organic polymer consisting from polysiloxane part and a part consisting from organic chain which does not contain silicon. One of two parts is the main one, while the other part is grafted on the main chain at least of 30% of water and one propellent and organic solvent which content is from 0 to 25 wt.%. The weight percent is relatively determined by total weight of composition in aerosol. Hairspray is not foamed and does not possess the property of powdering or impuring the hair. EFFECT: improved hair styling. 45 cl, 2 tbl, 3 ex
Loiasis, a filarial pathogen exclusively endemic in central and western Africa, causes a wide spectrum of symptoms. Understanding the breadth of its clinical manifestations is of importance for adequate patient care and to understand its disease burden. Recurring transient pain in the oral cavity was reported as a self-perceived symptom of loiasis in in-depth interviews of patients in a high transmission region in Gabon. Pain was described as stabbing in character and transient for a few days in its temporal course. A quantitative epidemiological survey indicated that transient tooth pain was experienced by 22% of patients infected with Loa loa. Among those individuals, it was exclusively reported by patients suffering from migratory loiasis (24%). Similar findings have been previously described for other filarial pathogens, indicating that transient swellings of the periodontium and the soft tissue of the oral cavity may explain this symptom reported by patients with migratory loiasis.
Currently the most commonly performed definitive treatment for symptomatic esophago-gastric junction outflow obstruction is a laparoscopic esophageal myotomy (LEM). In this procedure the outer longitudinal and inner circular muscle fibers of the distal esophagus and proximal stomach are divided, releasing the spasm and resulting in an open lumen. Although this procedure is effective in relieving troubles swallowing and in improving esophageal emptying, it is often accompanied by the development of GERD (as the muscle division results in incompetence of the antireflux barrier, the lower esophageal sphincter). For this reason a laparoscopic esophageal myotomy is most often accompanied by a fundoplication, in which part of the fundus of the stomach is folded around the distal esophagus and sutured in place, recreating a flap-valve mechanism. (It is best to perform this at the time of the laparoscopic myotomy as reoperation in that area is difficult). The fundoplication however may be imperfect, and may result in some degree of outflow obstruction itself or fail to control reflux. LEM results in 80% to 90% global patient satisfaction; but 10-20% continue to experience moderate dysphagia and 10-35% will have GERD by esophageal pH testing.

Others have evaluated the possibility of surgically dividing the muscle fibers from within the esophagus, using an endoscope rather than a laparoscope, in an animal model. The first human experience was reported in Japan using a per-oral endoscope to (a) incise the mucosa in the proximal esophagus as an entry point, (b) create a submucosal tunnel downwards, (c) perform an esophageal myotomy of the distal esophageal circular muscle, and (d) close the mucosal entry site with clips. The creation of the submucosal tunnel for some distance before the myotomy is a safety measure, so that should the mucosal closure fail, native tissues will appose and help seal any leak (rather like the Z-entry for a thoracentesis). Subsequent to this initial report, multiple single-arm studies have reported that the technique is safe and is associated with excellent medium-term relief of dysphagia..

In the POEM technique no fundoplication is performed. By the endoscopic creation of an esophageal submucosal tunnel the inner circular muscle layer could be easily visualized and in contrast to conventional laparoscopic esophageal myotomy, the authors described the division of only this inner circular esophageal muscle layer leaving the outer longitudinal muscle layer intact. The distal esophagus is exposed in LEM, hence disrupting the attachments to the diaphragm. These attachments contribute to the overall antireflux mechanism. It is hypothesized that by only dividing the inner circular muscle, and not disrupting the contribution of the outer longitudinal muscle or the diaphragmatic attachments to the antireflux mechanism, POEM may not have the same potential for reflux as a LEM. If this is the case then an antireflux procedure may not be needed after the POEM procedure.
A rescue system includes a receiver, an emergency medical staff arrival time estimation unit, an acquisition unit, a user arrival time estimation unit, and a transmitter. The receiver receives a request for rescue of a rescued person and rescued person location information. The emergency medical staff arrival time estimation unit estimates an emergency medical staff arrival time at which an emergency medical staff arrives at the rescued person based on the rescued person location information. The acquisition unit acquires user location information of a registered user that is a candidate for a rescuer. The user arrival time estimation unit estimates the user arrival time when the registered user arrives at the rescued person based on the user location information. The transmitter transmits the request for rescue to the registered user that is able to arrive earlier than the emergency medical staff.
Patients receive the same intervention as in Arm I with the addition of 18 ounces of lean beef provided by the study to each subject. Subjects will be encouraged to consume the lean beef and lectures will incorporate healthy beef consumption into each lesson and cooking demonstration.
FIELD: medicine, veterinary science. ^ SUBSTANCE: invention concerns veterinary medicine. The method involves production of the antigen, inactivation and addition of adjuvant. Target affected organs of fallen nutrias are taken from a local epizootic nidus, and suspension is prepared from them. Inoculation in differentially diagnostic media is carried out subsequently, pure cultures of the germs are evolved, cultures Pseudomonas aeruginosa and Enterococcus faecalis are separately grown in meat infusion broth with glucose added up to 0.2% concentration with titre of 4-5 milliard microbe cells per 1 cm3. The material is inactivated by adding formalin up to 0.4-0.5% final concentration and then exposed to 37C for 72-96 hours. The cultures are mixed in equal proportion. Aluminium hydroxide (20% by volume) is added to the culture. The components are thoroughly mixed, packed and sealed. ^ EFFECT: method is simple and allows of obtaining highly immunogenic specific vaccine. ^ 1 tbl, 1 ex